Enlarge (credit: Getty | Bloomberg) A small biotech company called Brainstorm Cell Therapeutics Inc. is among the first companies considering selling an experimental therapy directly to patients under the “right to try” measure, signed into law late last month. And if the company moves forward, it may give its unproven therapy a price tag in the ballpark of $300,000, according to a recent report by Bloomberg, The experimental stem cell-based therapy, called NurOwn, is aimed at treating amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease).